Prostate Cancer
Conditions
Brief summary
This study is a single-center registry study collecting clinical data regarding the treatment of PSMA-positive metastatic castration-resistant prostate cancer treated with PSMA radionuclide therapy per the treating physician's discretion. Clinical data from candidates for or who undergo the PSMA procedure at Methodist Dallas Medical Center from August 2022 to August 2027 will be collected after discharge and patients will undergo clinical follow-up per the treating physician's discretion.
Detailed description
This study is a single-center registry study collecting clinical data regarding the treatment of PSMA-positive metastatic castration-resistant prostate cancer treated with PSMA radionuclide therapy per the treating physician's discretion. Clinical data from candidates for or who undergo the PSMA procedure at Methodist Dallas Medical Center from August 2022 to August 2027 will be collected after discharge and patients will undergo clinical follow-up per the treating physician's discretion. Participants will be followed for two years following the first PSMA procedure. During these visits, participants will also be asked to report any change in their medications. Participants will not need to visit the study doctor more often than their usual treatment unless they have other medical needs. However, if participants experience any significant change in their medical condition they may be asked to have additional tests such as computed tomography (CT) scans, blood tests, etc.
Interventions
DRUGPSMA radionuclide therapy
Collect clinical data related to treatment of PSMA-positive metastatic castration-resistant prostate cancer treated with PSMA radionuclide therapy
Sponsors
Methodist Health System
Study design
Observational model
OTHER
Time perspective
OTHER
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* 1\. \>18 years of age * 2\. Diagnosed with PSMA-positive metastatic castration-resistant prostate cancer and - has consented to undergo PSMA nuclear therapy per the treating physician. Specifically: * Metastatic or Locally Advanced AND Inoperable * Clear disease progression on PSMA-PET/CT * PSMA-PET/CT scan positive disease within 6 weeks * Labs: * Hemoglobin: \>8 g/dL * White blood cell count: \>2K cells/µL * Platelet (Thrombocyte) count: \>75 x 109/L * No prior therapy with Radium-223 Dichloride
Exclusion criteria
* Patients who do not meet the Inclusion Criteria laid out in section 4.2 will be excluded from the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| collect clinical data related to treatment of PSMA-positive metastatic castration-resistant prostate cancer | Clinical data from candidates for or who undergo the PSMA procedure at Methodist Dallas Medical Center from August 2022 to August 2027 will be collected after discharge and patients will undergo clinical follow-up per the treating physician's discretion | To collect clinical data related to patient characteristics, treatment responses and survival outcomes related to the treatment of PSMA-positive metastatic castration-resistant prostate cancer treated with PSMA radionuclide therapy |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORAlexandru Bageac, MD
Methodist Health System
Outcome results
None listed